Staphylococcus aureus Bacterial Resistance to Silver Nanoparticle: The Emergence and the Mechanisms of Resistance by Valentin, Elizabeth
 
 STAPHYLOCOCCUS AUREUS  
BACTERIAL RESISTANCE TO 
SILVER NANOPARTICLE: 
THE EMERGENCE AND  






A thesis submitted in fulfilment of the requirements for the award of 









The ithree Institute 
Faculty of Science 
University of Technology Sydney 
July 2020 

Certificate of Original Authorship 
I, Elizabeth Valentin, declare that this thesis, is submitted in fulfilment of the 
requirements for the award of Doctor of Philosophy in the ithree Institute, Faculty of 
Science at the University of Technology Sydney.  
This thesis is wholly my own work unless otherwise reference or acknowledged. In 
addition, I certify that all information sources and literature used are indicated in the 
thesis.  
This document has not been submitted for qualifications at any other academic 
institution.  
This research is supported by the Australian Government Research Training Program, 
Australian Research Council Discovery Project (DP 180100474), the UTS International 
























 “I praise You because I am fearfully and wonderfully made; Your works are 
wonderful, I know that full well” – Psalm 139: 14 
It is an incredible feeling to finally write this acknowledgment section as it indicates that 
my PhD journey is closing to an end after 3.5 years. Looking back, it has been a very 
tough and challenging journey, and at the same time, very rewarding, particularly 
because I changed path from biochemical engineering to microbiology. This PhD work 
and completion would only be a sole imagination without the support and help from the 
people that I would like to give my gratitude to.  
First, I would like to thank my primary supervisor, Dr. Cindy Gunawan. Thank you for 
taking me on board and for your trust in me to do this PhD project in the first place. 
Thank you for being a role model in an academic field, something I did not expect to 
have when I enrolled as a PhD student. I would say that you are probably one of the 
most accessible supervisors I have ever have so far and the one that is always up for 
discussion. Also, I would never forget your excitement in science, regardless of 
explainable or unexplainable the results were. This gave me a boost to stay excited 
and curious as well. Lastly, thank you for reading and improving the quality of my 
writing.  
Huge thanks and appreciation for my co-supervisor, Dr. Amy Bottomley, who taught me 
fundamental molecular microbiology techniques in the laboratory. This gave me hands-
on experiences that I truly appreciate. Thank you for putting a big effort for honest 
feedbacks on mostly everything, but particularly for this thesis. Your invaluable 
feedback has helped me to improve my work. I would like to also thank my other co-
supervisor, Prof. Liz Harry. Thank you for asking questions that quite unthinkable 
sometimes and letting me ponder the bigger picture of my work.  
Ultimately, I would like to thank all my supervisors for their tremendous support and 
understanding especially when my husband and I were expecting our little one towards 
the end of my PhD. 
I would like to thank my thesis reviewer, Prof. Kwang-Leong Choy from University of 
College London (UCL), United Kingdom and Prof. Cordelia Selomulya from University 
of New South Wales (UNSW), Australia for their honest and constructive comments. 
Thank you for giving this thesis different perspective and help elevate the significance 
of the work. 
ii 
I am very grateful for Assoc. Prof. Scott Rice, Dr. Gayatri Shankar Chilambi, Dr. Xinyi 
Zhu, Dr. Xianghui Liu, and Dr. Cai Zhao. Thank you for the discussion, feedback, and 
help particularly during the genomic and transcriptomic work, and also for the 
opportunity to work at SCELSE, Singapore.  
My acknowledgement also goes to the member of Harry Lab (Daniel Bouzo, Dr. 
Isabella Hadjuk, Dr. Kenardy Kusuma, Dr. Matthew Payne, Dr. Nural Cocketin, and Dr. 
Shirin Ansari) as well as Gunawan Lab (Kevin Yonathan, Oliver McNeilly, Dr. Riti 
Mann, and Tina Nguyen) with whom I have the honour of meeting and working with. 
Thank you for the technical and non-technical discussion, support, and friendship 
throughout my PhD journey. 
I am thankful for technical staffs in Bioscience Laboratory Level 7 (Mercedes 
Ballesteros and Sarah Osvath) who manage the laboratory and ensure that we all can 
do our lab work in a proper and safe way. Thank you as well for administration staffs 
(Meggie Leung, Shannon Hawkins, and Shima Baradaran Vahdat) for their assistance 
in many administrative works.  
I express my gratitude to the office squad (Ahmed Mohammed, Daniela Gaio, Jessica 
Pedersen, Rami Mazraani, Regan Hayward, Susanna Luo, and William King). Thank 
you for the scientific and many non-scientific talks that we had, and for the distraction 
and entertainment that we all definitely need during this PhD candidature. Thank you 
for the friendship that I will surely cherish all the time.  
Acknowledgment also extends to Rosie Hicks, whom I have met through IMNIS 
program. Thank you for being so humble and grounded, something that I will always 
remember. Thank you for the relationship that we have built so far and for the advices 
especially about interpersonal skills.  
I am deeply thankful for my families in Christ, Indonesian Christian Macquarie 
Fellowship (Christopher and Kaitlin Antonny, Christopher Townsend, Ellen Paulin 
Hutagaol, Emman Marpaung, Febrina Sandra, Harry Tjondro and Raniwidia Basileia, 
Inggrika Remalia Kaban, Jessica Levina Halim, Julie Holmes, Kian and Liza Holik, 
Lyndle Hardstaff, Merinda Naraswari, Pauline Djojo, Rafael Alvin, Renny Dese, Richard 
Kusnadi, and Vanie Patiung), Trinity Chapel Macquarie (Dave and Sue Steele-Smith, 
Inggrid Wei, Tim Mildenhall, Vonnie and Yonnie Ho), Macquarie Chapel Indonesian 
Church (Ari and Sophia Supala, Gitta Ernestine, Pudi Muliawan and Irene Marius, 
Steven Lee and Irene Tedjasaputra, and Tirta and Lina Hadinata). Thank you for your 
love, friendship, support, and especially prayers.  
 
iii 
My appreciation also extends to my family back home, especially for Mamski and 
Papski, who let their youngest and only daughter to move far away from home 8 years 
ago to pursue her MS and now PhD degree. Thank you for believing in what I would 
like to pursue, acquire, and choose back then and now.   
Although my words will not be sufficient to describe it, I would like to express my 
profound gratefulness to Roy Simorangkir, my best friend and partner in life. Thank you 
for being the core of my support system and being a great exemplary of persistence, 
consistence, and hard work. Thank you for being my solid rock and always have my 
back during times when I feel like giving up. Thank you for celebrating with me during 
good times but also praying and crying with me during difficult times. Above all, you 
have taught and showed me the unconditional love that Jesus himself gave to us and I 
am truly grateful to have met you in this life, and even more to share this life with you. I 
love you with all my heart.  
Last but not least, Thank you Jesus Christ, for granting me my faith and identity in You 
alone. I am honoured and privileged to be able to call You Father and to be liberated 
from the identity other than in You. Praising You for all the people You have 







The widespread use of silver nanoparticle (NAg) in consumer products has prompted 
major concerns for bacterial resistance phenomena. Scholarly works have reported the 
natural ability of bacteria to develop resistance to the antibacterial nanoparticle. While 
the adaptation mechanisms have been studied in Gram-negative bacteria, it remains 
largely unexplored in Gram-positive bacteria. This work seeks to investigate the 
phenomena of NAg resistance in Staphylococcus aureus, a Gram-positive bacterium, 
to unravel the development and mechanisms of resistance in one of the WHO-listed 
priority pathogens. 
Herein, the work found that S. aureus has the ability to evolve stable resistance traits, 
reducing the potency of NAg, upon prolonged exposure. Higher NAg concentrations 
are required to inhibit the bacterium growth when compared to the wild-type strain. A 
whole genome analysis of the resistant strain revealed mutation in gene that encodes 
the purine operon repressor protein. The mutation was thought to be responsible, at 
least in part, for the physiological adaptation of S. aureus, that is, the defence 
responses that manifest even in the absence of the nanoparticle. The role of this 
mutation was supported by transcriptomic analysis, whereby, increased expression of 
the whole purine synthesis operon were detected in the resistant strain. This, along 
with the observed changes in the expression of other metabolic genes (the pyrimidine, 
nitrogen, and capsular polysaccharide), highlight a metabolic adaptation to the likely 
disruptions in bacterial fitness. 
The transcriptomic analysis also gives insights into the roles of specific cellular 
pathways, most likely responsible for the resistance characteristics. Our study found 
increased expression of genes that encode transporter proteins, ROS (reactive oxygen 
species) scavenger enzymes in the resistant strain and genes that are associated with 
the assembly of the iron-sulphur (Fe-S) clusters, one of the main cellular targets of 
NAg. For the latter, the upregulation was detected in the clusters’ main synthesis genes 
(suf system) as well as in the iron and cysteine acquisition genes. Collectively, the 
adaptation mechanisms involve attempt by the bacterium to neutralize the over-
production of ROS, while simultaneously recovering the damaged Fe-S clusters and 
facilitating silver efflux.  
In summary, the knowledge generated herein provides insights into the emergence and 
molecular basis of NAg resistance in a bacterium that has been perceived to have no, 
or very low resistance tendency to NAg. The fundamental knowledge will allow 
vi 
development of technologies to overcome the resistance phenomena and to inform 
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